Journal articles on the topic 'EGFR'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 journal articles for your research on the topic 'EGFR.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
Chemmalar, S., A. R. Intan Shameha, Che Azurahanim Che Abdullah, Nor Asma Ab Razak, Loqman Mohamad Yusof, Mokrish Ajat, Kim Wei Chan, and Md Zuki Abu Bakar Zakaria. "Busting the Breast Cancer with AstraZeneca’s Gefitinib." Advances in Pharmacological and Pharmaceutical Sciences 2023 (December 4, 2023): 1–26. http://dx.doi.org/10.1155/2023/8127695.
Full textRengifo, Charles E., Rancés Blanco, Damián Blanco, Mercedes Cedeño, Milagros Frómeta, and Enrique Rengifo Calzado. "Immunohistochemical Characterization of Three Monoclonal Antibodies Raised against the Epidermal Growth Factor and Its Receptor in Non-Small-Cell Lung Cancer: Their Potential Use in the Selection of Patients for Immunotherapy." Journal of Biomarkers 2013 (December 11, 2013): 1–9. http://dx.doi.org/10.1155/2013/627845.
Full textJezierska, Michalina, Anna Owczarzak, and Joanna Stefanowicz. "Dimethylarginines in Children after Anti-Neoplastic Treatment." Medicina 58, no. 1 (January 11, 2022): 108. http://dx.doi.org/10.3390/medicina58010108.
Full textAl-Shaibani, Eshrak, Taylor Young, Eshetu Atenafu, Verna Cheung, Safwan Alsibai, Vikas Gupta, Dawn C. Maze, Marta Beata Davidson, Aniket Banker, and Hassan Sibai. "Impact of Kidney Dysfunction on Overall Survival in Myeloproliferative Neoplasms: A Single-Center Retrospective Study." Blood 142, Supplement 1 (November 28, 2023): 6439. http://dx.doi.org/10.1182/blood-2023-189318.
Full textMaennling, Amaia Eleonora, Mehmet Kemal Tur, Marcus Niebert, Torsten Klockenbring, Felix Zeppernick, Stefan Gattenlöhner, Ivo Meinhold-Heerlein, and Ahmad Fawzi Hussain. "Molecular Targeting Therapy against EGFR Family in Breast Cancer: Progress and Future Potentials." Cancers 11, no. 12 (November 20, 2019): 1826. http://dx.doi.org/10.3390/cancers11121826.
Full textHuang, Hsien-Neng, Pin-Feng Hung, Yai-Ping Chen, and Chia-Huei Lee. "Leucine Zipper Downregulated in Cancer-1 Interacts with Clathrin Adaptors to Control Epidermal Growth Factor Receptor (EGFR) Internalization and Gefitinib Response in EGFR-Mutated Non-Small Cell Lung Cancer." International Journal of Molecular Sciences 25, no. 3 (January 23, 2024): 1374. http://dx.doi.org/10.3390/ijms25031374.
Full textNicholson, Christopher J., Samuel J. Roth, Arudhir Singh, Caitlin Brown, Simon P. Fricker, Jon Hu, and Samantha Dale Strasse. "Abstract C052: Circumventing EGFR inhibitor resistance in NSCLC using transomics." Molecular Cancer Therapeutics 22, no. 12_Supplement (December 1, 2023): C052. http://dx.doi.org/10.1158/1535-7163.targ-23-c052.
Full textKumar, Sachin, Jeff Vassallo, Kalpana Nattamai, Jose A. Cancelas, and Hartmut Geiger. "EGFR Signaling in Osteoblasts Regulates Circadian Rhythm of HSPC in Circulation." Blood 126, no. 23 (December 3, 2015): 665. http://dx.doi.org/10.1182/blood.v126.23.665.665.
Full textZhou, Caicun, Fumio Imamura, Ying Cheng, Isamu Okamoto, Byoung Chul Cho, Meng Chih Lin, Margarita Majem, et al. "Early clearance of plasma EGFR mutations as a predictor of response to osimertinib and comparator EGFR-TKIs in the FLAURA trial." Journal of Clinical Oncology 37, no. 15_suppl (May 20, 2019): 9020. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.9020.
Full textLee, Eugine, Padraich Flahardy, Cameron Vergato, Stephen Siecinski, Justin Chen, Charles O’Donnell, Graeme Hodgson, Defne Yarar, and Thomas McCauley. "Abstract 1726: Targeted epigenomic control of MYC as a strategy to treat EGFR inhibitor-resistant NSCLC." Cancer Research 84, no. 6_Supplement (March 22, 2024): 1726. http://dx.doi.org/10.1158/1538-7445.am2024-1726.
Full textGecht, Judith, Ioannis Tsoukakis, Kim Kricheldorf, Frank Stegelmann, Martine Klausmann, Martin Griesshammer, Holger Schulz, et al. "Kidney Dysfunction Is Associated with Thrombosis and Disease Severity in Myeloproliferative Neoplasms: Implications from the German Study Group for MPN Bioregistry." Cancers 13, no. 16 (August 13, 2021): 4086. http://dx.doi.org/10.3390/cancers13164086.
Full textHoffman, P., and C. Carlin. "Adenovirus E3 protein causes constitutively internalized epidermal growth factor receptors to accumulate in a prelysosomal compartment, resulting in enhanced degradation." Molecular and Cellular Biology 14, no. 6 (June 1994): 3695–706. http://dx.doi.org/10.1128/mcb.14.6.3695-3706.1994.
Full textHoffman, P., and C. Carlin. "Adenovirus E3 protein causes constitutively internalized epidermal growth factor receptors to accumulate in a prelysosomal compartment, resulting in enhanced degradation." Molecular and Cellular Biology 14, no. 6 (June 1994): 3695–706. http://dx.doi.org/10.1128/mcb.14.6.3695.
Full textSimmons, Daniel, Maral DerSarkissian, Rahul Shenolikar, Min-Jung Wang, Angela Lax, Aruna Muthukumar, François Laliberté, and Mei Sheng Duh. "Real-world outcomes among patients with epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors versus immunotherapy or chemotherapy in first-line setting." Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020): e19345-e19345. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.e19345.
Full textSimmons, Daniel, Maral DerSarkissian, Rahul Shenolikar, Min-Jung Wang, Angela Lax, Aruna Muthukumar, François Laliberté, and Mei Sheng Duh. "Real-world outcomes among patients with epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors versus immunotherapy or chemotherapy in first-line setting." Journal of Clinical Oncology 38, no. 29_suppl (October 10, 2020): 281. http://dx.doi.org/10.1200/jco.2020.38.29_suppl.281.
Full textMulherin, Brian Patrick, Jia Zeng, Anupama Vasudevan, Erin Alwon, Mike Gart, Simon Blanc, and Stephen G. Divers. "Assessing quality of care in early stage resected stage non-small cell lung cancer (NSCLC): An evaluation of epidermal growth factor receptor (EGFR) testing and adjuvant (adj) therapy (tx)." Journal of Clinical Oncology 42, no. 16_suppl (June 1, 2024): 8072. http://dx.doi.org/10.1200/jco.2024.42.16_suppl.8072.
Full textvan de Stadt, Eveline Annette, Maqsood Yaqub, Robert C. Schuit, Imke H. Bartelink, Anke F. Leeuwerik, Lothar A. Schwarte, Adrianus J. de Langen, Harry Hendrikse, and Idris Bahce. "Relationship between Biodistribution and Tracer Kinetics of 11C-Erlotinib, 18F-Afatinib and 11C-Osimertinib and Image Quality Evaluation Using Pharmacokinetic/Pharmacodynamic Analysis in Advanced Stage Non-Small Cell Lung Cancer Patients." Diagnostics 12, no. 4 (April 1, 2022): 883. http://dx.doi.org/10.3390/diagnostics12040883.
Full textPardo Aranda, Nuria, Jordi Remon, Alex Martinez Marti, Ana Maria Martinez de Castro, Susana Cedres Perez, Alejandro Navarro, Eulalia Scheenaard, et al. "Outcome of EGFR mutant patirnts included in a clinical trial after progression on EGFR TKI." Journal of Clinical Oncology 35, no. 15_suppl (May 20, 2017): e20555-e20555. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e20555.
Full textHartman, Zachary, Werner J. Geldenhuys, and Yehenew M. Agazie. "A specific amino acid context in EGFR and HER2 phosphorylation sites enables selective binding to the active site of Src homology phosphatase 2 (SHP2)." Journal of Biological Chemistry 295, no. 11 (February 4, 2020): 3563–75. http://dx.doi.org/10.1074/jbc.ra119.011422.
Full textSharabi, Omri, Tomer Ventura, Rivka Manor, Eliahu D. Aflalo, and Amir Sagi. "Epidermal Growth Factor Receptor in the Prawn Macrobrachium rosenbergii: Function and Putative Signaling Cascade." Endocrinology 154, no. 9 (September 1, 2013): 3188–96. http://dx.doi.org/10.1210/en.2013-1259.
Full textKassel, Karen M., Nancy A. Schulte, and Myron L. Toews. "Modulation of epidermal growth factor receptor binding to human airway smooth muscle cells by glucocorticoids and β2-adrenergic receptor agonists." American Journal of Physiology-Lung Cellular and Molecular Physiology 296, no. 4 (April 2009): L693—L699. http://dx.doi.org/10.1152/ajplung.90446.2008.
Full textSorkin, A. "Internalization of the epidermal growth factor receptor: role in signalling." Biochemical Society Transactions 29, no. 4 (August 1, 2001): 480–84. http://dx.doi.org/10.1042/bst0290480.
Full textSantoni-Rugiu, Melchior, Urbanska, Jakobsen, Stricker, Grauslund, and Sørensen. "Intrinsic resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance." Cancers 11, no. 7 (July 1, 2019): 923. http://dx.doi.org/10.3390/cancers11070923.
Full textChouaid, Christos, Laura Luciani, Katell Le Lay, and Gerard De Pouvourville. "Cost-effectiveness analysis of afatinib vs gefitinib in EGFR-mutated population with advanced non-small-cell lung cancer." Journal of Clinical Oncology 35, no. 15_suppl (May 20, 2017): e20548-e20548. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e20548.
Full textShum, Elaine, Yasir Elamin, Karen L. Reckamp, Zofia Piotrowska, Julia Rotow, Daniel S. Tan, Koichi Goto, et al. "Abstract CT184: Emerging evidence of activity of BLU-945 in patients with advanced EGFR-mutant NSCLC utilizing circulating tumor DNA (ctDNA) in the phase 1/2 SYMPHONY study." Cancer Research 82, no. 12_Supplement (June 15, 2022): CT184. http://dx.doi.org/10.1158/1538-7445.am2022-ct184.
Full textYu, Xiaochun, Kailash D. Sharma, Tsuyoshi Takahashi, Ryo Iwamoto, and Eisuke Mekada. "Ligand-independent Dimer Formation of Epidermal Growth Factor Receptor (EGFR) Is a Step Separable from Ligand-induced EGFR Signaling." Molecular Biology of the Cell 13, no. 7 (July 2002): 2547–57. http://dx.doi.org/10.1091/mbc.01-08-0411.
Full textAbrahams, Beynon, Anthonie Gerber, and Donavon Charles Hiss. "Combination Treatment with EGFR Inhibitor and Doxorubicin Synergistically Inhibits Proliferation of MCF-7 Cells and MDA-MB-231 Triple-Negative Breast Cancer Cells In Vitro." International Journal of Molecular Sciences 25, no. 5 (March 6, 2024): 3066. http://dx.doi.org/10.3390/ijms25053066.
Full textAhn, Myung-Ju, Silvia Park, Jong-Mu Sun, Jin Seok Ahn, Keunchil Park, Emma J. Langley, Phillip Sangwook Kim, Sharat Singh, and Steve Lockton. "Roles of cMET/ErbB3 activation and overexpression in the development of resistance to EGFR inhibitors in NSCLC patients." Journal of Clinical Oncology 31, no. 15_suppl (May 20, 2013): 11113. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.11113.
Full textRamalingam, Suresh S., James C. H. Yang, Chee Khoon Lee, Takayasu Kurata, Dong-Wan Kim, Thomas John, Naoyuki Nogami, et al. "Osimertinib As First-Line Treatment of EGFR Mutation–Positive Advanced Non–Small-Cell Lung Cancer." Journal of Clinical Oncology 36, no. 9 (March 20, 2018): 841–49. http://dx.doi.org/10.1200/jco.2017.74.7576.
Full textTavera, Luz, Stefanie Schalm, John Campbell, Jian Guo, Clare Medendorp, Maxine Chen, Faris Albayya, et al. "Abstract 3328: Antitumor activity of BLU-945 and BLU-701 as single agents and in combination in EGFR L858R-driven models of NSCLC." Cancer Research 82, no. 12_Supplement (June 15, 2022): 3328. http://dx.doi.org/10.1158/1538-7445.am2022-3328.
Full textGuardiola, Salvador, Mireia Díaz-Lobo, Jesús Seco, Jesús García, Laura Nevola, and Ernest Giralt. "Peptides Targeting EGF Block the EGF-EGFR Interaction." ChemBioChem 17, no. 8 (January 25, 2016): 702–11. http://dx.doi.org/10.1002/cbic.201500525.
Full textPal, Arpita S., Alejandra Agredo, Nadia A. Lanman, Jihye Son, Ikjot Singh Sohal, Manvir Bains, Chennan Li, Jenna Clingerman, Kayla Gates, and Andrea L. Kasinski. "Loss of KMT5C Promotes EGFR Inhibitor Resistance in NSCLC via LINC01510-Mediated Upregulation of MET." Cancer Research 82, no. 8 (April 11, 2022): 1534–47. http://dx.doi.org/10.1158/0008-5472.can-20-0821.
Full textNakagawa, Kazuhiko, Edward B. Garon, Takashi Seto, Makoto Nishio, Santiago Ponce Aix, Chao-Hua Chiu, Keunchil Park, et al. "RELAY: A multinational, double-blind, randomized Phase 3 study of erlotinib (ERL) in combination with ramucirumab (RAM) or placebo (PL) in previously untreated patients with epidermal growth factor receptor mutation-positive (EGFRm) metastatic non-small cell lung cancer (NSCLC)." Journal of Clinical Oncology 37, no. 15_suppl (May 20, 2019): 9000. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.9000.
Full textShu, Catherine A., Koichi Goto, Byoung Chul Cho, Frank Griesinger, James Chih-Hsin Yang, Enriqueta Felip, John Xie, et al. "CHRYSALIS-2: A phase 1/1b study of lazertinib as monotherapy and in combination with amivantamab in patients with EGFR-mutant NSCLC." Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021): TPS9132. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.tps9132.
Full textChung, Tsai-Hua, Jong-Kai Hsiao, Ming Yao, Szu-Chun Hsu, Hon-Man Liu, and Dong-Ming Huang. "Ferucarbotran, a carboxydextran-coated superparamagnetic iron oxide nanoparticle, induces endosomal recycling, contributing to cellular and exosomal EGFR overexpression for cancer therapy." RSC Advances 5, no. 109 (2015): 89932–39. http://dx.doi.org/10.1039/c5ra18810e.
Full textThomas, C. Y., M. Jameson, and A. Beckler. "Interaction of EGFR and IGF-1R signals to modulate the anti-proliferative and biochemical responses of head and neck squamous cancer (HNSCC) cells to EGFR inhibitors." Journal of Clinical Oncology 25, no. 18_suppl (June 20, 2007): 6045. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.6045.
Full textHarvey, R. Donald, Val R. Adams, Tyler Beardslee, and Patrick Medina. "Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings." Journal of Oncology Pharmacy Practice 26, no. 6 (June 20, 2020): 1461–74. http://dx.doi.org/10.1177/1078155220931926.
Full textKim, Ji Min, Jun Ho Ji, Young Saing Kim, Suee Lee, Sung Yong Oh, Seok Jae Huh, Choon Hee Son, et al. "rhEGF Treatment Improves EGFR Inhibitor-Induced Skin Barrier and Immune Defects." Cancers 12, no. 11 (October 25, 2020): 3120. http://dx.doi.org/10.3390/cancers12113120.
Full textOhmori, Tohru, Toshimitsu Yamaoka, Koichi Ando, Sojiro Kusumoto, Yasunari Kishino, Ryou Manabe, and Hironori Sagara. "Molecular and Clinical Features of EGFR-TKI-Associated Lung Injury." International Journal of Molecular Sciences 22, no. 2 (January 14, 2021): 792. http://dx.doi.org/10.3390/ijms22020792.
Full textJazieh, Abdul Rahman, Huseyin Cem Onal, Daniel Shao-Weng Tan, Ross A. Soo, Kumar Prabhash, Amit Kumar, Reto Huggenberger, and Byoung Chul Cho. "Real-world global data on targeting epidermal growth factor receptor mutations in stage III non-small-cell lung cancer: the results of the KINDLE study." Therapeutic Advances in Medical Oncology 14 (January 2022): 175883592211227. http://dx.doi.org/10.1177/17588359221122720.
Full textUrbanska, Edyta M., Morten Grauslund, Peter R. Koffeldt, Sarah L. B. Truelsen, Johan O. Löfgren, Junia C. Costa, Linea C. Melchior, Jens B. Sørensen, and Eric Santoni-Rugiu. "Real-World Data on Combined EGFR-TKI and Crizotinib Treatment for Acquired and De Novo MET Amplification in Patients with Metastatic EGFR-Mutated NSCLC." International Journal of Molecular Sciences 24, no. 17 (August 23, 2023): 13077. http://dx.doi.org/10.3390/ijms241713077.
Full textAddeo, Alfredo, Maximilian Hochmair, Urska Janzic, Elizabeth Dudnik, Andriani Charpidou, Adam Płużański, Tudor Ciuleanu, et al. "Treatment patterns, testing practices, and outcomes in the pre-FLAURA era for patients with EGFR mutation-positive advanced NSCLC: a retrospective chart review (REFLECT)." Therapeutic Advances in Medical Oncology 13 (January 2021): 175883592110598. http://dx.doi.org/10.1177/17588359211059874.
Full textAgulnik, Jason S., Goulnar Kasymjanova, Carmela Pepe, Manjusha Hurry, Ryan N. Walton, Lama Sakr, Victor Cohen, and David Small. "Real-World Pattern of Treatment and Clinical Outcomes of EGFR-Mutant Non-Small Cell Lung Cancer in a Single Academic Centre in Quebec." Current Oncology 28, no. 6 (December 7, 2021): 5179–91. http://dx.doi.org/10.3390/curroncol28060434.
Full textZubair, Tanzida, and Debasish Bandyopadhyay. "Small Molecule EGFR Inhibitors as Anti-Cancer Agents: Discovery, Mechanisms of Action, and Opportunities." International Journal of Molecular Sciences 24, no. 3 (January 31, 2023): 2651. http://dx.doi.org/10.3390/ijms24032651.
Full textNicholson, Christopher J., Arudhir Singh, Caitlin Westberg Brown, Simon P. Fricker, Jon Hu, and Samantha Dale Strasser. "Abstract LB063: An integrated transomics approach reveals significant differences between EGFR inhibitors with the potential to identify novel targets to overcome EGFR resistance." Cancer Research 83, no. 8_Supplement (April 14, 2023): LB063. http://dx.doi.org/10.1158/1538-7445.am2023-lb063.
Full textSacchi, Elizabeth, You Li, Vincent A. Miller, Melissa D. Curtis, and Siraj Mahamed Ali. "Real-world racial disparities in EGFR testing and third-generation EGFR TKI use among U.S. patients with stage IV NSCLC." Journal of Clinical Oncology 40, no. 28_suppl (October 1, 2022): 124. http://dx.doi.org/10.1200/jco.2022.40.28_suppl.124.
Full textWada, I., W. H. Lai, B. I. Posner, and J. J. Bergeron. "Association of the tyrosine phosphorylated epidermal growth factor receptor with a 55-kD tyrosine phosphorylated protein at the cell surface and in endosomes." Journal of Cell Biology 116, no. 2 (January 15, 1992): 321–30. http://dx.doi.org/10.1083/jcb.116.2.321.
Full textKelly, Karen, Nasser K. Altorki, Wilfried E. E. Eberhardt, Mary E. R. O'Brien, David R. Spigel, Lucio Crinò, Chun-Ming Tsai, et al. "Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non–Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial." Journal of Clinical Oncology 33, no. 34 (December 1, 2015): 4007–14. http://dx.doi.org/10.1200/jco.2015.61.8918.
Full textMiettinen, Päivi, Päivi Ormio, Elina Hakonen, Meenal Banerjee, and Timo Otonkoski. "EGF receptor in pancreatic β-cell mass regulation." Biochemical Society Transactions 36, no. 3 (May 21, 2008): 280–85. http://dx.doi.org/10.1042/bst0360280.
Full textYamazaki, Tetsuo, Kristien Zaal, Dale Hailey, John Presley, Jennifer Lippincott-Schwartz, and Lawrence E. Samelson. "Role of Grb2 in EGF-stimulated EGFR internalization." Journal of Cell Science 115, no. 9 (May 1, 2002): 1791–802. http://dx.doi.org/10.1242/jcs.115.9.1791.
Full text